blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1897533

EP1897533 - Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.02.2009
Database last updated on 09.09.2024
Most recent event   Tooltip13.02.2009Application deemed to be withdrawnpublished on 18.03.2009  [2009/12]
Applicant(s)For all designated states
Revotar Biopharmaceuticals AG
Neuendorfstrasse 24a
16761 Henningsdorf / DE
[2008/11]
Inventor(s)01 / Aydt, Ewald
Lloyd-G-Wells-Str. 20
14163 Berlin / DE
02 / Bock, Daniel
Weissenburgstr. 8
30161 Hannover / DE
03 / Vollhardt, Karin
Am Eichenhain 16
16761 Henningsdorf / DE
04 / Wolff, Gerhard
Karl-Liebknecht-Str. 23
16548 Glienicke-Nordbahn / DE
 [2008/11]
Representative(s)Isenbruck, Günter
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Eastsite One
Seckenheimer Landstrasse 4
68163 Mannheim / DE
[N/P]
Former [2008/38]Isenbruck, Günter
Isenbruck, Bösl, Hörschler, Wichmann, Huhn Patentanwälte Theodor-Heuss-Anlage 12
68165 Mannheim / DE
Former [2008/11]Isenbruck, Günter
Theodor-Heuss-Anlage 12
68165 Mannheim / DE
Application number, filing date06120400.408.09.2006
[2008/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1897533
Date:12.03.2008
Language:EN
[2008/11]
Search report(s)(Supplementary) European search report - dispatched on:EP23.02.2007
ClassificationIPC:A61K8/60, A61Q19/08, A61Q19/00, A61Q17/00
[2008/11]
CPC:
A61Q19/08 (EP,US); A61K8/498 (EP,US); A61K8/602 (EP,US);
A61P17/00 (EP); A61Q17/00 (EP,US); A61Q19/00 (EP,US)
Designated contracting states[2008/47]
Former [2008/11]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verwendung von 1,6-Bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl]hexan zur Herstellung von kosmetischen Zusammensetzungen[2008/11]
English:Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions[2008/11]
French:Utilisation de 1,6-Bis[3-(3-carboxyméthylphényl)-4-(2-alpha-D-mannopyranosyl-oxy)-phényl]hexane pour la préparation des compositions cosmétiques.[2008/11]
Examination procedure16.09.2008Application deemed to be withdrawn, date of legal effect  [2009/12]
24.10.2008Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2009/12]
Fees paidPenalty fee
Additional fee for renewal fee
30.09.200803   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[DX]WO9701335  (TEXAS BIOTECHNOLOGY CORP [US], et al) [DX] 2-5,9-12,17-20 * page 7; compound A * * page 11, line 28 - page 14, line 18; examples 1,10; claim - *;
 [X]  - PHILIPP S ET AL, "Demonstration of antipsoriatic efficacy of a new topical formulation of a small molecule selectin antagonist bimosiamose", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 66TH ANNUAL MEETING OF THE SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; ST LOUIS, MO, USA; MAY 04 -07, 2005, (200504), vol. 124, no. 4, Suppl. S, ISSN 0022-202X, page A38, XP002418882 [X] 1-20 * abstract 228 *

DOI:   http://dx.doi.org/10.1111/j.0022-202X.2004.23539.x
 [X]  - PHILIPP S ET AL, "Demonstration of antipsoriatic efficacy of a new topical formulation of a small molecule selectin antagonist bimosiamose", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 35TH ANNUAL MEETING OF THE EUROPEAN-SOCIETY-FOR-DERMATOLOGICAL-RESEA RCH; TUBINGEN, GERMANY; SEPTEMBER 22 -24, 2005, (200509), vol. 125, no. 3, Suppl. S, ISSN 0022-202X, page A34, XP002418883 [X] 1-20 * abstract 197 *

DOI:   http://dx.doi.org/10.1111/j.0022-202X.2005.23763.x
 [X]  - MEALY N.E. ET AL, "Annual update 2003/2004- treatment of dermatological disorders", DRUGS OF THE FUTURE , 29(4), 393-436 CODEN: DRFUD4; ISSN: 0377-8282, (2004), XP002418884 [X] 1-20 * page 407 *
 [X]  - FRIEDRICH M ET AL, "Bimosiamose, a pan-selectin antagonist improves disease manifestation both in human psoriatic skin SCID mice and psoriatic patients: Selectin antagonists as a new treatment strategy for inflammatory diseases.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, INTERNATIONAL INVESTIGATIVE DERMATOLOGY 2003 : JOINT MEETING OF THE EUROPEAN SOCIETY FOR DERMATOLOGI; MIAMI BEACH, FLORIDA, USA; APRIL 30-MAY 04, 2003, (200307), vol. 121, no. 1, ISSN 0022-202X, page 0367, XP002418885 [X] 1-20 * abstract *

DOI:   http://dx.doi.org/10.1046/j.1523-1747.2003.12482.x
 [X]  - MARKUS FRIEDRICH ET AL, "Pan-selectin antagonism improves psoriasis manifestation in mice and man", ARCHIVES OF DERMATOLOGICAL RESEARCH ; FOUNDED IN 1869 AS ARCHIV FÜR DERMATOLOGIE UND SYPHILIS, SPRINGER-VERLAG, BE, (20060201), vol. 297, no. 8, ISSN 1432-069X, pages 345 - 351, XP019341197 [X] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00403-005-0626-0
 [X]  - "Press Release: First Positive Results With a New Topical Formulation of Bimosiamose in Psoriasis, will be presented at the European Congress of Psoriasis", (20041115), URL: HTTP://WWW.REVOTAR.DE/PDF/TOPICAL_PRESS_RELEASE_PARIS.PDF, (20070207), XP002418886 [X] 1-20 * the whole document *
 [X]  - "First Positive Results With a New Topical Formulation of Bimosiamose in Psoriasis, will be presented at the European Congress of Psoriasis", (20041021), URL: HTTP://WWW.BIOTOP.DE/NEWS/ARCHIV_DETAIL_E.ASP?QUICKSEARCH=&ABSOLUTEPAGE=11&ID=1294, (20070207), XP002418887 [X] 1-20 * the whole document *
 [X]  - "Texas Biotechnology and Revotar Pharmaceuticals AG Initiate Phase I Study with Novel Selectin Antagonist, TBC 1269", (20010626), URL: HTTP://IR.ENCYSIVE.COM/IREYE/IR_SITE.ZHTML?TICKER=ENCY&SCRIPT=460&LAYOUT=-6&ITEM_ID=236633, (20070207), XP002418888 [X] 1-20 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.